This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ESPAC-3 was a phase 3 randomized treatment trial evaluating chemotherapy regimens and clinical observation in patients with completely resected pancreatic cancer.
| Feature | ESPAC-3 |
|---|---|
| Condition | Pancreatic Cancer |
| Design | Randomized phase 3 trial |
| Primary purpose | Treatment |
| Allocation | Randomized |
| Lead sponsor | Royal Liverpool University Hospital |
| Sponsor type | OTHER_GOV |
2. Clinical Question
Population
Patients with completely resected pancreatic cancer.
Interventions
Fluorouracil, gemcitabine hydrochloride, leucovorin calcium, and clinical observation.
Comparator
The registry identifies clinical observation as one of the trial arms.
Primary question
Does the assigned treatment strategy affect overall survival?
3. Trial Design
Patients were assigned in a randomized phase 3 design.
The study included 3 arms.
The registry reports 1030 participants.
Primary completion date: 2008-04.
4. Endpoints
| Endpoint | Registry definition |
|---|---|
| Overall survival | Primary endpoint |
5. Statistical Methodology
The registry identifies overall survival as the primary endpoint. For randomized oncology trials with an overall survival endpoint, the statistical framework generally focuses on comparing time-to-event distributions between randomized groups.
Time-to-event analysis
Overall survival is typically analysed using methods that account for patients who are alive at the end of follow-up or lost to follow-up. Kaplan-Meier estimation describes survival over time, while comparative models such as Cox proportional-hazards models may summarize relative treatment effects.
The survival function represents the probability that the event time exceeds a specified time point.
6. Planned Analysis
The registry identifies overall survival as the primary endpoint but does not report posted statistical analyses or endpoint results on ClinicalTrials.gov.
For an endpoint of this type, a typical analysis would compare overall survival between randomized groups using time-to-event methods, accounting for censoring and estimating uncertainty around treatment comparisons. Results have not been posted on ClinicalTrials.gov.
7. Statistical Methods Explained
Why is overall survival analysed as a time-to-event endpoint?
Patients may experience death at different times, and some observations may be censored. Time-to-event methods incorporate the timing of events rather than only whether an event occurred.
What does randomization contribute statistically?
Randomization creates treatment groups whose outcomes can be compared while reducing systematic differences between groups at baseline.
Why is censoring important?
Censoring allows patients with incomplete follow-up information to contribute available survival information without assuming their future outcomes.
What does a hazard ratio represent?
A hazard ratio is a relative comparison of event rates over time under a statistical model. It is not the same as the percentage of patients who experience an event.
Why are confidence intervals important?
Confidence intervals describe uncertainty around an estimated treatment effect and help distinguish precise estimates from estimates with substantial uncertainty.
Why does a p-value not describe treatment magnitude?
A p-value addresses evidence against a statistical null hypothesis. It does not directly measure clinical importance or the size of an effect.
8. Limitations
- The registry does not report posted statistical analyses or results for the primary endpoint.
- The registry does not report median survival, confidence intervals, subgroup analyses, or safety results.
- Interpretation of overall survival requires the underlying event and censoring information, analysis population definitions, and prespecified statistical plan.
9. Why This Trial Matters Statistically
ESPAC-3 illustrates several important principles in clinical trial statistics:
| Concept | Application |
|---|---|
| Randomization | Comparison of treatment strategies in a phase 3 design |
| Overall survival | Time-to-event primary endpoint |
| Censoring | Required for incomplete follow-up observations |
| Survival models | Framework for analysing event timing |
10. Sources
- ClinicalTrials.gov record: NCT00058201
- PubMed: PubMed 22782416
- PubMed: PubMed 20823433
- PubMed: PubMed 31483448
- PubMed: PubMed 29068800